BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04660812 (AB680 Etrumadenant Zimberelimab Bevacizumab… in Metastatic Colorectal Cancer): BVCT ex-ante prediction vs. reported outcome

On 18 Jun 2023, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 2 Jun 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant yet commercially insufficient (non-superior) pending more cohorts data.

Clinical Trial

NCTID
NCT04660812
Acronym
ARC-9
Drug Name
AB680 Etrumadenant Zimberelimab Bevacizumab m-FOLFOX-6 regimen Regorafenib
Drug MoA
selective dual antagonist of the A2a and A2b receptors
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Metastatic Colorectal Cancer
Human Patients
227
Sponsor
Gilead Sciences / Arcus Bioscience
Phase
Phase 1 Phase 2

Prediction of , index 506

Prospective Prediction
Prediction Index
506
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
350 days in advance
Readout Data Interpretation
17.3% ORR and 19.7 months mOS (vs 19% ORR and 21.4months OS by the FOLFIRI/bevacizumab alone without zimberelimab as 2L mCRC treatment in the SPIRITT trial).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant yet commercially insufficient (non-superior) pending more cohorts data
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Phase
Phase 1, Phase 2
Status
Completed
Enrollment
227
Lead sponsor
Arcus Biosciences, Inc.
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG: AB680; DRUG: Etrumadenant; DRUG: Zimberelimab; DRUG: Bevacizumab; DRUG: m-FOLFOX-6 regimen; DRUG: Regorafenib
Design
Randomized · Parallel · Single
Primary purpose
Treatment
Start
2021-05-10
Primary completion
2025-09-05
Completion
2025-09-05
Primary outcomes
  • Cohort A and B - Progression-free Survival (PFS) (From randomization until death from any cause (up to approximately 3-7 years))
  • Cohort C - Objective Response Rate (ORR) (From randomization until death from any cause (up to approximately 3-7 years))
  • Number of Participants With Treatment-emergent Adverse Events (Up to approximately 10 Months)

NCT04660812 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials